A Study of Single Doses to Evaluate the Safety, Tolerability, Pharmacokinetics and Target Engagement of Nebulised GSK3008348 in Idiopathic Pulmonary Fibrosis Patients, Using Positron Emission Tomography (PET) Imaging

Trial Profile

A Study of Single Doses to Evaluate the Safety, Tolerability, Pharmacokinetics and Target Engagement of Nebulised GSK3008348 in Idiopathic Pulmonary Fibrosis Patients, Using Positron Emission Tomography (PET) Imaging

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs GSK 3008348 (Primary) ; GSK 2634673F
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 02 Oct 2017 Planned End Date changed from 10 Jan 2019 to 21 Dec 2018.
    • 02 Oct 2017 Planned primary completion date changed from 10 Jan 2019 to 21 Dec 2018.
    • 27 Jul 2017 Planned End Date changed from 28 Dec 2018 to 10 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top